Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.87 |
| ▸ | HTR2C | P28335 | 3/20 | 0.87 |
| ▸ | HTR7 | P34969 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | HTR6 | P50406 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328582 | 0.95 | HTR2A (0.87) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| SCHEMBL9375973 | 0.91 | HTR2A (1.00) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| Glemanserin SCHEMBL120012 | 0.90 | HTR2A (1.00) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| Glemanserin SCHEMBL7838106 | 0.89 | HTR2A (0.97) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| SCHEMBL9328976 | 0.88 | HTR2A (0.84) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| SCHEMBL9328969 | 0.87 | HTR2A (0.82) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| SCHEMBL9179569 | 0.87 | HTR2A (0.82) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL9649750 | 0.86 | HTR2A (0.80) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| SCHEMBL9329079 | 0.84 | HTR2A (0.76) | HTR2AHTR2CHTR7KDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL9649783 | 0.83 | HTR2A (0.74) | HTR2AHTR2CHTR7KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0325063-B1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMA (US) | 1994-03-09 | — | — | EP | claimed |
| US-4908369-A | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | claimed |
| EP-0337136-A2 | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-18 | — | — | EP | claimed |
| EP-0319962-A2 | Piperidinyl methanol derivatives for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-14 | — | — | EP | claimed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | UMN PHARMA INC. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-0325063-B1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMA (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5169096-A | Serotonin antagonists, analgesics | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5106855-A | Method for the treatment of glaucoma | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-04-21 | — | — | US | disclosed |
| EP-0434021-A2 | 4-Piperidine methanol derivatives for the treatment of glaucoma | MERRELL PHARMACEUTICALS INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| US-5021428-A | Novel chemical compounds for the prophylactic treatment of migraine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-06-04 | — | — | US | disclosed |
| US-4912117-A | Therapy for varient angina | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-27 | — | — | US | disclosed |
| US-4908369-A | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0208235-B1 | N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0337136-A2 | Piperidine derivatives in the treatment of extrapyramidal side effects associated with neuroleptic therapy | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0325063-A1 | Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-07-26 | — | — | EP | disclosed |
| EP-0319962-A2 | Piperidinyl methanol derivatives for the treatment of anxiety | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-06-14 | — | — | EP | disclosed |
| US-4783471-A | N-aralkyl piperidine methanol derivatives and the uses thereof | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-11-08 | — | — | US | disclosed |
| EP-0208235-A1 | N-Aralkyl piperidinemethanol derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075974-A1 | AGENT FOR PROPHYLAXIS AND TREATMENT OF PANCREATITIS | HTR2A, HTR2B, HTR2C | HTR2A 1/4885HTR2C 3/4885HTR7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.